ClinicalTrials.gg
RecruitingNCT07918690Updated Nov 5, 2026

dPmax for Predicting Right Ventricular Failure After Left Ventricular Assist Device Implantation

An observational study in Ventricular Dysfunction, Right, sponsored by Pınar Kırdemir. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Pınar Kırdemir · Observational

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 5, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
89
Ages
18 Years and older
Sex
All
01

Study summary

This single-center, prospective observational study aims to evaluate whether dPmax, a measure of the maximum rate of arterial pressure rise obtained through pulse contour analysis, can predict right ventricular failure after left ventricular assist device (LVAD) implantation in adults. Measurements collected during routine monitoring before and after anesthesia induction will be analyzed alongside preoperative echocardiographic findings. The primary outcome is right ventricular failure within 30 days after surgery, assessed using Mechanical Circulatory Support-Academic Research Consortium (MCS-ARC) criteria. Secondary objectives include comparing the predictive performance of dPmax with the ratio of tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/SPAP) and identifying an optimal dPmax threshold for predicting right ventricular failure. No additional invasive procedures will be performed for research purposes.

02

Conditions studied

  • Ventricular Dysfunction, Right
03

In context

Ventricular Dysfunction, Right

90 studies on the registry are indexed under Ventricular Dysfunction, Right; 28 are open to participants now.

This study's planned enrollment of 89 is below the median of 100 across 51 observational studies indexed under Ventricular Dysfunction, Right.

Browse Ventricular Dysfunction, Right studies →

Lead sponsor

This is the only study on the registry with Pınar Kırdemir as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged 18 years or older with advanced heart failure who are scheduled for left ventricular assist device (LVAD) implantation at Ankara Bilkent City Hospital. Eligible patients of any sex will be consecutively enrolled during the study period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Scheduled for left ventricular assist device (LVAD) implantation.
  • Availability of the clinical data required for the study.
  • Willingness and ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Congenital heart disease associated with transposition of the great arteries.
  • Ongoing extracorporeal membrane oxygenation (ECMO) or extracorporeal ventricular assist device (ExVAD) support immediately before LVAD implantation.
  • Severe aortic regurgitation, severe peripheral arterial disease, or and uncontrolled tachyarrhythmia that may interfere with arterial waveform analysis.
  • Unwillingness to participate or cognitive impairment preventing .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
89 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testArterial Pulse Contour Analysis

    Arterial pulse contour analysis will be performed using the PulsioFlex monitoring system during routine invasive arterial monitoring for LVAD implantation. dPmax, representing the maximum rate of rise in arterial pressure, will be recorded before and after anesthesia induction. Absolute values and the relative change between measurements will be evaluated for their association with right ventricular failure within 30 days after surgery. No additional arterial catheterization or invasive procedures will be performed for research purposes.

06

What researchers measure

Primary outcomes

  1. Right Ventricular Failure Within 30 Days After LVAD Implantation

    Time frame: 30 days after surgery.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Sep 2029, 39 months after the start.

Of 25 observational studies under Ventricular Dysfunction, Right, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 26. This study's planned 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2026
First posted
Nov 5, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Nov 2029
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07918690
Lead sponsor
Pınar Kırdemir
Responsible party
Pınar Kırdemir (MD, Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital) — Sponsor-investigator
First posted
Nov 5, 2026
Start date
Jun 3, 2026
Primary completion
Sep 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion